Your AI-Trained Oncology Knowledge Connection!
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses factors that physicians should take into account when administering frontline treatment options to patients with chronic lymphocytic leukemia.
Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses niraparib in patients with platinum-sensitive recurrent ovarian cancer
Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy options for patients with bladder cancer, but mentions how other agents are evolving the landscape. Iyer shared this insight during the 2016 OncLive® State of the Science Summit on Genitourinary Cancers.
Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.
Vitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.
Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia.
Tanios Bekaii-Saab, MD, a professor of Medicine at Mayo Clinic, discusses sequencing regorafenib (Stivarga) and TAS-102 (Lonsurf) in metastatic colorectal cancer (mCRC).
Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the safety profile of Yttrium-90, particularly when combined with capecitabine as a treatment for patients with liver-dominant metastatic colorectal cancer.
Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses agents being explored as treatments for patients with prostate cancer, including apalutamide and PARP inhibitors.
Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.
Wassim Abida, MD, PhD, assistant member and assistant attending physician in the Genitourinary Oncology Program at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with prostate cancer.
William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.
Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses how she has seen various agents impact quality of life (QOL) when used to treat patients with breast cancer.
Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.
Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses Y-90 in metastatic castration resistant colorectal cancer (mCRC).
Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses combination treatments currently being tested for the treatment of patients with ovarian cancer.
Raymond U. Osarogiagbon, MD, FACP, Boston Baskin Cancer Foundation, Baptist Memorial Medical Group, discusses treating patients with lung cancer that have the potential to be cured.
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the treatment landscape of recurrent head and neck cancer.
Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact that the FALCON trial findings have had on the field of hormone receptor-positive breast cancer.
Edgardo S. Santos, MD, medical oncology, internal medicine, Boca Raton Regional Hospital, discusses exciting advancements in the field of lung cancer. Santos shared this insight during the 2016 OncLive State of the Science Summit on Lung Cancer.
Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses radiation therapy in recurrent head and neck cancer.
Philippe Moreau, MD, head of the Hematology Department, University Hospital of Nantes, France, discusses the combination treatments being used to treat patients with multiple myeloma.
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, compares the toxicity profiles of regorafenib and TAS-102, which are both used to treat patients with metastatic colorectal cancer.
Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.
